0001209191-23-057712.txt : 20231207 0001209191-23-057712.hdr.sgml : 20231207 20231207160355 ACCESSION NUMBER: 0001209191-23-057712 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231205 FILED AS OF DATE: 20231207 DATE AS OF CHANGE: 20231207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Conner Edward R. CENTRAL INDEX KEY: 0001691265 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41498 FILM NUMBER: 231472351 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Third Harmonic Bio, Inc. CENTRAL INDEX KEY: 0001923840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 834553503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1700 MONTGOMERY STREET STREET 2: SUITE 210 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 2097272457 MAIL ADDRESS: STREET 1: 1700 MONTGOMERY STREET STREET 2: SUITE 210 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-05 0 0001923840 Third Harmonic Bio, Inc. THRD 0001691265 Conner Edward R. 1700 MONTGOMERY STREET SUITE 210 SAN FRANCISCO CA 94111 0 1 0 0 Chief Medical Officer 1 Common Stock 2023-12-05 4 M 0 4790 4.20 A 4790 D Common Stock 2023-12-05 4 S 0 4790 10.0339 D 0 D Employee Option Grant (right to buy) 4.20 2023-12-05 4 M 0 4790 0.00 A 2032-07-27 Common Stock 4790 378498 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated May 15, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. 25% of the total shares vested on June 6, 2023, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. /s/ Julie Person, Attorney-in-Fact 2023-12-07